Cai Jing, Wang Wanning, Cong Dan, Bai Yuansong, Zhang Wenlong
Department of Pediatrics, China-Japan Union Hospital of Jilin University, Changchun 130033, China.
Department of Nephrology, the First Hospital of Jilin University, Changchun 130021, China.
Crit Rev Oncol Hematol. 2025 Mar;207:104617. doi: 10.1016/j.critrevonc.2025.104617. Epub 2025 Jan 11.
HER2-positive gastric cancer (GC), a unique molecular subtype, has garnered significant interest in recent years. Here, we review clinical trial data on advanced HER2-positive GC from the past 15 years. Trastuzumab plus standard chemotherapy remain the first-line treatment. The initial survival benefits conferred by immune checkpoint inhibitors plus trastuzumab and standard chemotherapy are encouraging. The combination of ramucirumab and mono-chemotherapy, as well as the antibody conjugated drug trastuzumab deruxtecan, is the recommended second-line regimen. Treatment with immune checkpoint inhibitors plus ramucirumab and mono-chemotherapy shows promise. Despite the limited treatment options for third line and beyond, development of novel therapeutic strategies is expected. Although clinical cure of advanced HER2-positive GC is unlikely, current clinical studies offer valuable insight into regimens that prolong survival.
人表皮生长因子受体2（HER2）阳性胃癌（GC）是一种独特的分子亚型，近年来备受关注。在此，我们回顾过去15年中晚期HER2阳性GC的临床试验数据。曲妥珠单抗联合标准化疗仍是一线治疗方案。免疫检查点抑制剂联合曲妥珠单抗和标准化疗带来的初始生存获益令人鼓舞。雷莫西尤单抗与单药化疗联合，以及抗体偶联药物曲妥珠单抗德曲妥珠单抗，是推荐的二线治疗方案。免疫检查点抑制剂联合雷莫西尤单抗和单药化疗的治疗显示出前景。尽管三线及以上治疗选择有限，但新型治疗策略的研发仍值得期待。虽然晚期HER2阳性GC临床治愈不太可能，但目前的临床研究为延长生存期的治疗方案提供了有价值的见解。
